697 related articles for article (PubMed ID: 32254090)
21. Regulating Interactions Between Targeted Nanocarriers and Mononuclear Phagocyte System via an Esomeprazole-Based Preconditioning Strategy.
Belhadj Z; He B; Fu J; Zhang H; Wang X; Dai W; Zhang Q
Int J Nanomedicine; 2020; 15():6385-6399. PubMed ID: 32922007
[TBL] [Abstract][Full Text] [Related]
22. Nanoparticle approaches to combating drug resistance.
Moon JH; Moxley JW; Zhang P; Cui H
Future Med Chem; 2015 Aug; 7(12):1503-10. PubMed ID: 26334205
[TBL] [Abstract][Full Text] [Related]
23. Poly(ethylene glycol)-modified nanocarriers for tumor-targeted and intracellular delivery.
van Vlerken LE; Vyas TK; Amiji MM
Pharm Res; 2007 Aug; 24(8):1405-14. PubMed ID: 17393074
[TBL] [Abstract][Full Text] [Related]
24. Recent Advances in Targeted Tumor Chemotherapy Based on Smart Nanomedicines.
Qin SY; Zhang AQ; Zhang XZ
Small; 2018 Nov; 14(45):e1802417. PubMed ID: 30247806
[TBL] [Abstract][Full Text] [Related]
25. Controlling and Monitoring Intracellular Delivery of Anticancer Polymer Nanomedicines.
Battistella C; Klok HA
Macromol Biosci; 2017 Oct; 17(10):. PubMed ID: 28444959
[TBL] [Abstract][Full Text] [Related]
26. Ligand-targeted particulate nanomedicines undergoing clinical evaluation: current status.
van der Meel R; Vehmeijer LJ; Kok RJ; Storm G; van Gaal EV
Adv Drug Deliv Rev; 2013 Oct; 65(10):1284-98. PubMed ID: 24018362
[TBL] [Abstract][Full Text] [Related]
27. Tumor-Targeting Glycol Chitosan Nanoparticles for Cancer Heterogeneity.
Ryu JH; Yoon HY; Sun IC; Kwon IC; Kim K
Adv Mater; 2020 Dec; 32(51):e2002197. PubMed ID: 33051905
[TBL] [Abstract][Full Text] [Related]
28. Nanomedicines for cancer therapy: current status, challenges and future prospects.
Bor G; Mat Azmi ID; Yaghmur A
Ther Deliv; 2019 Feb; 10(2):113-132. PubMed ID: 30678550
[TBL] [Abstract][Full Text] [Related]
29. Biological rationale for the design of polymeric anti-cancer nanomedicines.
Zhou Y; Kopeček J
J Drug Target; 2013 Jan; 21(1):1-26. PubMed ID: 23009337
[TBL] [Abstract][Full Text] [Related]
30. Targeted nanomedicine for cancer therapeutics: Towards precision medicine overcoming drug resistance.
Bar-Zeev M; Livney YD; Assaraf YG
Drug Resist Updat; 2017 Mar; 31():15-30. PubMed ID: 28867241
[TBL] [Abstract][Full Text] [Related]
31. Multifunctional nanomedicine platform for concurrent delivery of chemotherapeutic drugs and mild hyperthermia to ovarian cancer cells.
Taratula O; Dani RK; Schumann C; Xu H; Wang A; Song H; Dhagat P; Taratula O
Int J Pharm; 2013 Dec; 458(1):169-80. PubMed ID: 24091153
[TBL] [Abstract][Full Text] [Related]
32. Aptamer-guided nanomedicines for anticancer drug delivery.
Alshaer W; Hillaireau H; Fattal E
Adv Drug Deliv Rev; 2018 Sep; 134():122-137. PubMed ID: 30267743
[TBL] [Abstract][Full Text] [Related]
33. Quantitative and high drug loading of self-assembled prodrug with defined molecular structures for effective cancer therapy.
Tang J; Zeng Z; Yan J; Chen C; Liu J; Feng X
J Control Release; 2019 Aug; 307():90-97. PubMed ID: 31185233
[TBL] [Abstract][Full Text] [Related]
34. PEGylation: a promising strategy to overcome challenges to cancer-targeted nanomedicines: a review of challenges to clinical transition and promising resolution.
Hussain Z; Khan S; Imran M; Sohail M; Shah SWA; de Matas M
Drug Deliv Transl Res; 2019 Jun; 9(3):721-734. PubMed ID: 30895453
[TBL] [Abstract][Full Text] [Related]
35. Regulating the surface poly(ethylene glycol) density of polymeric nanoparticles and evaluating its role in drug delivery in vivo.
Du XJ; Wang JL; Liu WW; Yang JX; Sun CY; Sun R; Li HJ; Shen S; Luo YL; Ye XD; Zhu YH; Yang XZ; Wang J
Biomaterials; 2015 Nov; 69():1-11. PubMed ID: 26275857
[TBL] [Abstract][Full Text] [Related]
36. New Strategies in the Design of Nanomedicines to Oppose Uptake by the Mononuclear Phagocyte System and Enhance Cancer Therapeutic Efficacy.
Zhou Y; Dai Z
Chem Asian J; 2018 Nov; 13(22):3333-3340. PubMed ID: 29441706
[TBL] [Abstract][Full Text] [Related]
37. Tuning of poly-S-nitrosated human serum albumin as superior antitumor nanomedicine.
Ishima Y; Fang J; Kragh-Hansen U; Yin H; Liao L; Katayama N; Watanabe H; Kai T; Suenaga A; Maeda H; Otagiri M; Maruyama T
J Pharm Sci; 2014 Jul; 103(7):2184-2188. PubMed ID: 24846171
[TBL] [Abstract][Full Text] [Related]
38. P-glycoprotein-targeted photodynamic therapy boosts cancer nanomedicine by priming tumor microenvironment.
Mao C; Li F; Zhao Y; Debinski W; Ming X
Theranostics; 2018; 8(22):6274-6290. PubMed ID: 30613297
[TBL] [Abstract][Full Text] [Related]
39. Dual Stable Nanomedicines Prepared by Cisplatin-Crosslinked Camptothecin Prodrug Micelles for Effective Drug Delivery.
Li Y; Lu H; Liang S; Xu S
ACS Appl Mater Interfaces; 2019 Jun; 11(23):20649-20659. PubMed ID: 31117440
[TBL] [Abstract][Full Text] [Related]
40. Poly(ethylene glycol)-block-poly(ε-caprolactone)-and phospholipid-based stealth nanoparticles with enhanced therapeutic efficacy on murine breast cancer by improved intracellular drug delivery.
He X; Li L; Su H; Zhou D; Song H; Wang L; Jiang X
Int J Nanomedicine; 2015; 10():1791-804. PubMed ID: 25784805
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
